Quantitation of PD-L1 staining on tumor and immune cells from pre-treatment biopsies demonstrated no correlation between the frequency of PD-L1-positive tumor or immune cells and pathologic response to neoadjuvant therapy (Fig. 4A, B, Supplementary Figs. 2 and 3). This evidence concerns the gene CD274 and neoplasm.